Lunai Bioworks Inc Dossier
Qualitative Analysis
Business overview
Lunai Bioworks Inc. (NASDAQ: LNAI), formerly known as Renovaro Inc. and Enochian BioSciences, is a pre-clinical stage biotechnology and TechBio company operating at the intersection of artificial intelligence, national security, and biology. The company focuses on AI-powered biodefense, drug discovery, and advanced diagnostics. It operates through three primary subsidiaries: Renovaro Biosciences (developing genetically modified cellular and immunotherapy technologies), Renovaro Cube (focusing on AI-driven early cancer detection), and BioSymetrics (an AI-powered drug discovery and precision neurology platform acquired in April 2025). Lunai's core technology platforms include the Augusta™ AI platform for precision neurology and the Elion platform for phenotype-based drug discovery.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Deploying the AI-enabled Augusta platform (combining Contingent AI, large toxicity databases, and in vivo testing) for chemical threat assessment under a multi-year U.S. government defense contract, and establishing the Pathfinder Consortium to accelerate chemical countermeasure discovery.
Expected impact: Positions the company to target U.S. procurement programs sized between $400 million and $1.2 billion per program, while securing non-dilutive federal funding.
Advancing early-stage therapeutic candidates and drug delivery technologies targeting central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, and rare genetic epilepsies, by pairing biological target identification with blood-brain barrier (BBB) crossing delivery mechanisms.
Expected impact: Overcomes the critical BBB delivery bottleneck in CNS drug development, improving translational success and opening pathways for pharmaceutical licensing and partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire a multi-jurisdictional CNS-focused patent portfolio (including the Pelerin and Oncotelic patent families covering heterocyclic compounds, anti-TGF-beta agents, and intranasal/combination delivery technologies) to expand IP assets for CNS programs and bolster the company's equity position.
Financial impact: Paid entirely in equity by issuing eight shares of Series B Convertible Preferred Stock with an aggregate stated value of $20,000,000, carrying a senior liquidation preference and converting at $1.50 per share.
To acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's disease drug assets, addressing a critical bottleneck in CNS drug development by enabling compounds to cross the BBB and activate specifically inside the brain.
Financial impact: Structured as a Series B Convertible Preferred transaction with an aggregate value of $20,000,000 at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation.
Strategic Partnerships
Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's human-derived 3D brain organoid systems to create an integrated translational engine for neurology drug discovery, initially focusing on Parkinson's disease and rare genetic epilepsies.
Terms: Supported by a newly awarded grant from the LouLou Foundation (specific financial terms and grant amount were not disclosed).
Aims to integrate and standardize patient-led rare disease datasets to build rare disease patient cohorts, identify defined patient subgroups, and activate trial-ready cohorts for pharmaceutical and biotechnology partnerships.
Terms: Specific financial terms were not disclosed.
Consolidates siloed U.S. toxicology, military, federal, and biotech capabilities to accelerate chemical countermeasure discovery and federal stockpiling, collaborating with experts from Harvard University, Brigham and Women's Hospital, the University of Utah, Purdue University, and the University of Colorado.
Terms: Aims to compress countermeasure development to approximately 36 months to target U.S. procurement programs sized between $400 million and $1.2 billion.